Paris: Bharat Biotech Chairman and Managing Director Krishna Ella said on Saturday that the Phase III trial of the COVID-19 nasal vaccine has been completed and the company will submit its data to the Drugs Controller General of India (DCGI) next month. In an exclusive interview, Dr. Ella said, “We have just completed a clinical trial, a data analysis is underway, next month, we will submit the data to the regulatory agency. If all goes well, then We will get permission and the vaccine will be launched. This will be the world’s first clinically proven nasal COVID-19 vaccine.”
Paris | We've completed a clinical trial, data analysis is going on. We'll submit the data to regulatory agency. If everything is okay, we'll get permission to launch & it will be world's 1st clinically proven nasal COVID-19 vaccine: Dr Krishna Ella, Chairman & MD, Bharat Biotech pic.twitter.com/stha9oXZ3R
— ANI (@ANI) June 19, 2022
Dr. Ella was in Paris as a speaker at Viva Technology 2022, where India was declared the Country of the Year. It is to be known that in January this year, the Drug Controller of India had given permission to Bharat Biotech to conduct a standalone phase III trial on its nasal corona vaccine. On the booster dose of Kovid-19, Dr. Ella said that those who have taken the second dose must definitely take the booster dose.
He said, “A booster dose of a vaccine gives immunity. I always say that a booster dose is a miracle dose for every vaccination. Even in the first children, two doses do not give much immunity, but the third dose in children Gives an amazing response to . It has to be controlled more intelligently.”